Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eribulin mesylate - Eisai Co Ltd

Drug Profile

Eribulin mesylate - Eisai Co Ltd

Alternative Names: B-1939; B-1939 mesylate; E-7386; E-7389; ER-086526; Eribrin; Halaven; Halichondrin B Analog; NSC-707389; TECERIS

Latest Information Update: 19 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd; Harvard University; Japan Agency for Medical Research and Development
  • Developer Academic and Community Cancer Research United; Asan Medical Center; Big Ten Cancer Research Consortium; Eisai Co Ltd; Emory University; Icahn School of Medicine at Mount Sinai; Medica Scientia Innovation Research; Merck & Co; National Cancer Center Hospital East; National Cancer Institute (USA); Pfizer; PRISM Pharma Co
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Ketones; Macrocyclic compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Transcription factor modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Soft tissue sarcoma
  • Phase III Non-small cell lung cancer
  • Phase II Ewing's sarcoma; Glioblastoma; Haemangioendothelioma; Haemangiosarcoma
  • Phase I/II Colorectal cancer; Liver cancer; Malignant melanoma; Solid tumours
  • No development reported Ovarian cancer; Urogenital cancer
  • Discontinued Bladder cancer; Prostate cancer

Most Recent Events

  • 05 Dec 2023 Updated efficacy data from a phase Ib/II ENHANCE-1 trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
  • 24 Nov 2023 Eisai withdraw a phase I trial (In volunteers) in UK (PO), due to delay in availability of the IMP (NCT04840927) (EudraCT2020-005638-13)
  • 31 Aug 2023 Eisai completes a phase I pharmacokinetic trial (In volunteers) in the United Kingdom (PO, Tablet) (NCT05607537; EudraCT2022-000954-27)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top